NASDAQ:CTSO Cytosorbents (CTSO) Stock Price, News & Analysis $1.03 +0.01 (+0.98%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.00▼$1.0350-Day Range$0.70▼$1.2152-Week Range$0.70▼$2.55Volume19,891 shsAverage Volume124,977 shsMarket Capitalization$55.94 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cytosorbents alerts: Email Address Cytosorbents MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside94.2% Upside$2.00 Price TargetShort InterestBearish2.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.33) to ($0.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.08 out of 5 starsMedical Sector710th out of 910 stocksSurgical & Medical Instruments Industry83rd out of 95 stocks 3.5 Analyst's Opinion Consensus RatingCytosorbents has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCytosorbents has only been the subject of 2 research reports in the past 90 days.Read more about Cytosorbents' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.56% of the outstanding shares of Cytosorbents have been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.Change versus previous monthShort interest in Cytosorbents has recently decreased by 2.11%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTSO. Previous Next 1.4 News and Social Media Coverage News SentimentCytosorbents has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cytosorbents this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CTSO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Cytosorbents is held by insiders.Percentage Held by InstitutionsOnly 32.87% of the stock of Cytosorbents is held by institutions.Read more about Cytosorbents' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.33) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cytosorbents' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About Cytosorbents Stock (NASDAQ:CTSO)Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Read More CTSO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTSO Stock News HeadlinesAugust 31, 2024 | americanbankingnews.comCytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.comAugust 28, 2024 | americanbankingnews.comCytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.comSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 27, 2024 | globenewswire.comCytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment ConferenceAugust 16, 2024 | globenewswire.comCytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 14, 2024 | seekingalpha.comCytosorbents Corporation (CTSO) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | globenewswire.comCytoSorbents Reports Second Quarter 2024 Financial and Operational ResultsAugust 13, 2024 | globenewswire.comCytoSorbents Appoints Peter J. Mariani Chief Financial OfficerSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 12, 2024 | markets.businessinsider.comCytosorbents earnings preview: what Wall Street is expectingAugust 12, 2024 | msn.comCytosorbents Q2 2024 Earnings PreviewAugust 7, 2024 | globenewswire.comCytoSorbents to Report Second Quarter 2024 Operating and Financial ResultsAugust 1, 2024 | globenewswire.comCytoSorbents Announces Compliance with Nasdaq Minimum Bid Price RequirementJuly 30, 2024 | globenewswire.comCytoSorbents Unveils Newly Redesigned, Unified Company and Product WebsiteJuly 29, 2024 | finance.yahoo.comCytoSorbents Unveils Newly Redesigned, Unified Company and Product WebsiteJuly 17, 2024 | globenewswire.comCytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health CongressJuly 2, 2024 | globenewswire.comCytoSorbents Secures $20 Million Credit FacilityJune 5, 2024 | globenewswire.comCytoSorbents to Host its 2024 Virtual Annual Stockholders MeetingSee More Headlines Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:CTSO CUSIPN/A CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees220Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$3.00 Low Stock Price Target$1.00 Potential Upside/Downside+94.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,510,000.00 Net Margins-68.70% Pretax Margin-70.89% Return on Equity-131.84% Return on Assets-50.72% Debt Debt-to-Equity Ratio0.82 Current Ratio2.12 Quick Ratio1.71 Sales & Book Value Annual Sales$32.93 million Price / Sales1.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book3.32Miscellaneous Outstanding Shares54,306,000Free Float50,722,000Market Cap$55.94 million OptionableOptionable Beta0.57 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Phillip P. Chan M.D. (Age 54)Ph.D., CEO & Director Comp: $541.93kMr. Vincent J. Capponi M.S. (Age 66)President & COO Comp: $452.62kMs. Kathleen P. Bloch CPA (Age 69)M.B.A., Chief Financial Officer Comp: $395.43kDr. Efthymios N. Deliargyris FACC (Age 56)FESC, FSCAI, M.D., Chief Medical Officer Comp: $463.15kMs. Terri Anne Powers M.B.A.Vice President of Investor Relations & Corporate CommunicationsDr. Christian Steiner M.D.Executive Vice President of Sales & MarketingMr. Christopher Cramer M.B.A.M.S., Senior Vice President of Business DevelopmentDr. Irina B. Kulinets Ph.D. (Age 69)Senior Vice President of Global Regulatory Affairs Jodi HooverExecutiveDr. Robert H. Bartlett M.D. (Age 85)Co-Chairman of Cardiac Surgery Advisory Board & Consultant Comp: $54kMore ExecutivesKey CompetitorsAccurayNASDAQ:ARAYNeuroPaceNASDAQ:NPCEProfound MedicalNASDAQ:PROFNevroNYSE:NVRONyxoahNASDAQ:NYXHView All CompetitorsInsiders & InstitutionsSargent Investment Group LLCBought 67,181 shares on 8/10/2024Ownership: 2.640%CM Management LLCBought 25,000 shares on 8/2/2024Ownership: 1.565%Skylands Capital LLCSold 34,774 shares on 7/26/2024Ownership: 5.231%Alan D SobelBought 22,557 shares on 12/13/2023Total: $30,000.81 ($1.33/share)View All Insider TransactionsView All Institutional Transactions CTSO Stock Analysis - Frequently Asked Questions How have CTSO shares performed this year? Cytosorbents' stock was trading at $1.11 at the beginning of the year. Since then, CTSO shares have decreased by 7.2% and is now trading at $1.03. View the best growth stocks for 2024 here. How were Cytosorbents' earnings last quarter? Cytosorbents Co. (NASDAQ:CTSO) announced its quarterly earnings results on Tuesday, August, 13th. The medical research company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. The medical research company earned $9.89 million during the quarter, compared to the consensus estimate of $9.73 million. Cytosorbents had a negative trailing twelve-month return on equity of 131.84% and a negative net margin of 68.70%. What is Phillip Chan's approval rating as Cytosorbents' CEO? 11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend. Who are Cytosorbents' major shareholders? Top institutional investors of Cytosorbents include Skylands Capital LLC (5.23%), Sargent Investment Group LLC (2.64%) and CM Management LLC (1.57%). Insiders that own company stock include Phillip P Chan, Vincent Capponi, Al Kraus, Alan D Sobel, Michael G Bator, Edward Raymond Jones, Jiny Kim and Kathleen P Bloch. View institutional ownership trends. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE) and AbbVie (ABBV). This page (NASDAQ:CTSO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytosorbents With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
